467.55
price up icon2.02%   9.24
after-market Handel nachbörslich: 467.55
loading
Schlusskurs vom Vortag:
$458.31
Offen:
$459.62
24-Stunden-Volumen:
760.11K
Relative Volume:
0.74
Marktkapitalisierung:
$61.29B
Einnahmen:
$2.46B
Nettoeinkommen (Verlust:
$-319.09M
KGV:
-189.29
EPS:
-2.47
Netto-Cashflow:
$-52.09M
1W Leistung:
+5.61%
1M Leistung:
+45.87%
6M Leistung:
+86.58%
1J Leistung:
+67.48%
1-Tages-Spanne:
Value
$454.68
$467.71
1-Wochen-Bereich:
Value
$438.21
$467.71
52-Wochen-Spanne:
Value
$205.87
$467.71

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Firmenname
Alnylam Pharmaceuticals Inc
Name
Telefon
(617) 551-8200
Name
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Mitarbeiter
2,230
Name
Twitter
@alnylam
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
467.55 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.46 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
598.16 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
663.73 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.97 37.96B 3.81B -644.79M -669.77M -6.24

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-04 Hochstufung Oppenheimer Perform → Outperform
2025-08-04 Hochstufung Wolfe Research Underperform → Peer Perform
2025-07-30 Fortgesetzt Raymond James Outperform
2025-07-21 Eingeleitet Truist Buy
2025-03-31 Eingeleitet Redburn Atlantic Buy
2025-03-24 Hochstufung JP Morgan Neutral → Overweight
2024-11-12 Herabstufung Wolfe Research Peer Perform → Underperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-16 Hochstufung Goldman Neutral → Buy
2024-02-16 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-08 Eingeleitet Wells Fargo Equal Weight
2023-10-11 Herabstufung Oppenheimer Outperform → Perform
2023-09-29 Eingeleitet Raymond James Outperform
2023-05-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-26 Eingeleitet SMBC Nikko Neutral
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Buy
2022-09-09 Fortgesetzt Morgan Stanley Equal-Weight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-27 Herabstufung Guggenheim Buy → Neutral
2022-06-07 Eingeleitet William Blair Outperform
2022-04-25 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-03-01 Eingeleitet Citigroup Buy
2022-02-03 Hochstufung Guggenheim Neutral → Buy
2022-01-03 Hochstufung Piper Sandler Neutral → Overweight
2021-11-22 Hochstufung Goldman Neutral → Buy
2021-11-22 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Hochstufung Oppenheimer Perform → Outperform
2021-10-04 Hochstufung UBS Neutral → Buy
2021-08-04 Herabstufung Piper Sandler Overweight → Neutral
2021-02-22 Herabstufung Guggenheim Buy → Neutral
2021-02-12 Herabstufung Citigroup Buy → Neutral
2021-02-12 Bestätigt H.C. Wainwright Buy
2021-01-25 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-09-30 Fortgesetzt Berenberg Hold
2020-09-08 Eingeleitet Citigroup Buy
2020-08-11 Herabstufung Oppenheimer Outperform → Perform
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2020-05-07 Herabstufung JP Morgan Overweight → Neutral
2020-04-24 Fortgesetzt Evercore ISI Outperform
2020-03-19 Eingeleitet Berenberg Buy
2019-12-19 Bestätigt Chardan Capital Markets Buy
2019-11-20 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-06 Hochstufung Evercore ISI In-line → Outperform
2019-03-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-01-23 Eingeleitet UBS Neutral
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-13 Bestätigt Stifel Buy
2018-08-07 Hochstufung Stifel Hold → Buy
2018-05-04 Bestätigt Stifel Hold
2018-03-28 Eingeleitet Evercore ISI In-line
Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

pulisher
Aug 19, 2025

Alnylam Pharmaceuticals' Insider Sales: Compliance-Driven Moves or Subtle Signals of Strategic Shift? - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Alnylam Pharmaceuticals: Insider Selling as a Signal of Discipline, Not Distrust - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Insider Selling at Alnylam Pharmaceuticals: A Closer Look at Implications for Investors - AInvest

Aug 19, 2025
pulisher
Aug 19, 2025

Alnylam EVP Garg sells $1.3 million in stock - Investing.com

Aug 19, 2025
pulisher
Aug 19, 2025

Three Companies That Might Be Priced Below Their Estimated Value - simplywall.st

Aug 19, 2025
pulisher
Aug 19, 2025

Insider Selling at Alnylam Pharmaceuticals: Profit-Taking or a Warning Sign? - AInvest

Aug 19, 2025
pulisher
Aug 18, 2025

Alnylam Shares Surge on $730M Volume After FDA Approval Boosts Market Outlook and Analysts Raise Targets - AInvest

Aug 18, 2025
pulisher
Aug 18, 2025

Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionWall Street Watch & Scalable Portfolio Growth Ideas - beatles.ru

Aug 18, 2025
pulisher
Aug 18, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN

Aug 18, 2025
pulisher
Aug 18, 2025

Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com

Aug 18, 2025
pulisher
Aug 18, 2025

Free Genetic Tests May Aid People With Rare Kidney Disease - Medscape

Aug 18, 2025
pulisher
Aug 17, 2025

Insider Selling Trends in Nasdaq-Listed Companies: A Cautionary Lens on Alnylam, Boston Scientific, and CSX - AInvest

Aug 17, 2025
pulisher
Aug 16, 2025

Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals Inc. Reversal Rally May Surprise Bears2025 Market Overview & Technical Buy Zone Confirmations - beatles.ru

Aug 15, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD By Investing.com - Investing.com Australia

Aug 15, 2025
pulisher
Aug 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD - Investing.com

Aug 15, 2025
pulisher
Aug 14, 2025

Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY - simplywall.st

Aug 14, 2025
pulisher
Aug 13, 2025

Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat

Aug 13, 2025
pulisher
Aug 13, 2025

Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com

Aug 13, 2025
pulisher
Aug 12, 2025

Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam at Canaccord Genuity: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment - TipRanks

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace

Aug 12, 2025
pulisher
Aug 11, 2025

Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock - Yahoo Finance

Aug 11, 2025
pulisher
Aug 11, 2025

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance

Aug 11, 2025
pulisher
Aug 10, 2025

Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil

Aug 10, 2025
pulisher
Aug 07, 2025

Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st

Aug 07, 2025
pulisher
Aug 07, 2025

Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool

Aug 07, 2025
pulisher
Aug 06, 2025

Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com

Aug 06, 2025
pulisher
Aug 06, 2025

Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada

Aug 06, 2025
pulisher
Aug 06, 2025

Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive

Aug 06, 2025
pulisher
Aug 05, 2025

Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire

Aug 05, 2025
pulisher
Aug 05, 2025

Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st

Aug 05, 2025
pulisher
Aug 05, 2025

Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com

Aug 05, 2025
pulisher
Aug 04, 2025

Health Care Stocks See Gains On Strong Results And Approvals - Finimize

Aug 04, 2025
pulisher
Aug 04, 2025

Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada

Aug 04, 2025
pulisher
Aug 04, 2025

Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance

Aug 04, 2025
pulisher
Aug 04, 2025

Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest

Aug 04, 2025

Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Garg Pushkal
EVP Chief R&D
Aug 18 '25
Sale
453.27
1,396
632,759
21,676
Tanguler Tolga
EVP, Chief Commercial Officer
Aug 18 '25
Sale
453.27
1,396
632,759
29,466
Poulton Jeffrey V.
EVP, Chief Financial Officer
Aug 18 '25
Sale
453.27
2,274
1,030,727
50,121
Greenstreet Yvonne
Chief Executive Officer
Aug 18 '25
Sale
453.27
6,979
3,163,346
56,221
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Aug 18 '25
Sale
453.27
1,396
632,759
22,719
BONNEY MICHAEL W
Director
Aug 18 '25
Option Exercise
70.20
11,250
789,750
28,054
BONNEY MICHAEL W
Director
Aug 18 '25
Sale
450.00
11,250
5,062,500
16,804
$598.16
price up icon 1.21%
$663.73
price up icon 0.42%
biotechnology ONC
$313.97
price up icon 1.50%
$132.60
price up icon 2.43%
$110.77
price down icon 0.48%
Kapitalisierung:     |  Volumen (24h):